



PATENT
ATTORNEY DOCKET NO. 50304/063001

Certificate of Mailing: Date of Deposit: October 18, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Liane Malcos
Printed name of person mailing correspondence

Liane M. Malcos
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	SAINT-REMY et al.	Art Unit:	1644
Serial No.:	10/044,569	Examiner:	Maher M. Haddad
Filed:	January 11, 2002	Customer No.:	21559
Title:	METHOD AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING SYSTEMIC INFLAMMATORY RESPONSE SYNDROME		

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

Pursuant to 37 C.F.R. § 1.97(b)(4), this statement is being filed before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 18 October 2005



James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/063001
		Serial No.	10/044,569
		Applicant	SAINT-REMY et al.
		Filing Date	January 11, 2002
		Group	1644
		IDS Filed	October 18, 2005

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Begany, Timothy, "Monoclonal Antibody Improves Sepsis," Pulmonary Reviews.com, Vol. 5, No. 8 (2000) http://pulmonaryreviews.com/aug00/pr_aug00_TNF.html .					
	Martinell et al., "Peritonitis and Septic Shock – An Evaluation of Two Experimental Models in the Rat," <i>Eur. Surg. Res.</i> 17:160-166 (1985) (Abstract).					
	Near et al., "Characterization of an Anti-Digoxin Antibody Binding Site by Site-Directed <i>In Vitro</i> Mutagenesis," <i>Mol. Immunol.</i> 30:369-377 (1993).					
	Yan et al., "Therapeutic Effects of Lysophosphatidylcholine in Experimental Sepsis," <i>Nat. Med.</i> 10:161-167 (2004).					
	Yelton et al., "Affinity Maturation of the BR96 Anti-Carcinoma Antibody by Codon-Based Mutagenesis," <i>J. Immunol.</i> 155:1994-2004 (1995).					
	Ziegler et al., "Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody Against Endotoxin. A Randomized, Double-Blind, Placebo-Controlled Trial. The HA-1A Sepsis Study Group," <i>N. Engl. J. Med.</i> 324:429-436 (1991) (Abstract).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						